Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Turku University Hospital | OTHER_GOV |
| Central Finland Hospital District | OTHER |
| Tartu University Hospital | OTHER |
| University of Aarhus |
Not provided
Not provided
Not provided
This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.
Cholesterol-lowering statin drugs have been reported to lower proliferation activity in prostate cancer, delay occurrence of castration resistance and reduce the risk of prostate cancer death. Therefore, it is important to test statins' efficacy in addition to conventional prostate cancer treatment in a randomized, placebo-controlled trial.
This phase 3 randomized double-blind placebo-controlled trial will explore whether intervention with atorvastatin delays prostate cancer progression i.e. development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for metastatic or recurrent prostate cancer.
Secondary objectives include exploring whether atorvastatin lowers prostate cancer-specific or overall mortality compared to placebo, and to demonstrate whether changes in serum lipid parameters predict disease recurrence and occurrence of adverse genomic changes predicting castration resistance among prostate cancer patients during ADT.
The study recruitment target is 400 participants who start ADT as management of metastatic or recurrent prostate cancer. These men will be randomized 1:1 (200 + 200) to receive blinded study drug, either 80 mg of atorvastatin daily or placebo until disease recurrence i.e. development of castration resistance or for a maximum of five years.
The study will be carried out in collaboration between urological departments of University Hospitals in Finland as a project of the national FinnProstata study group, Herlev University Hospital in Denmark, Vestfold and Telemark hospitals in Norway and the Tartu University Hospital in Estonia.
Follow-up is continued until the primary end-point, development of castration resistance. After this the participants will be given the opportunity to voluntarily carry on with the blinded intervention for maximum time of ten year to observe effects on survival after development of castration resistance. Blinding will be lifted after the follow-up is complete for all study participants.
Castration resistance is defined as prostate-specific antigen (PSA) progression (three consecutive rises of PSA measured at least 1 week apart with two > 50% increases over the nadir and PSA > 2 ng/ml) or radiological disease progression (appearance of two or more lesions in bone scan or soft tissue enlargement as per RECIST criteria) with serum testosterone at castrate level (< 1.73 nmol/l; 50 ng/dl) during ADT.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Atorvastatin | Experimental | Capsules of atorvastatin. Daily dose of 80 mg for max. 10 years or until development of castration resistance. |
|
| Placebo | Placebo Comparator | Identical capsules as in the atorvastatin arm, but including no active ingredient. Used daily for max. 10 years or until development of castration resistance |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atorvastatin 80mg | Drug | Capsules including 80 mg of atorvastatin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Castration resistance | Castration resistance is defined as PSA progression (three consecutive PSA rises measured at least 1 week apart with two > 50% increases over the nadir and PSA > 2 ng/ml) or radiological disease progression (appearance of two or more lesions in bone scan or soft tissue enlargement as per RECIST criteria) with serum testosterone at castrate level (< 1.73 nmol/l; 50 ng/dl) during ADT. | From date of randomization until the date of first occurrence of castration resistance, assessed up to 60 months |
| Measure | Description | Time Frame |
|---|---|---|
| Lipid levels | Change in serum lipid levels during the intervention. Measured at baseline and in every follow-up visit. Results are blinded from the investigators and participants before the final analysis | From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 6 month intervals up to 60 months |
Not provided
Inclusion Criteria:
Histopathologically confirmed metastatic (radiologically confirmed bone or soft tissue metastasis or enlarged lymph nodes at minimum 15 mm in diameter beyond the pelvic lymph nodes) or recurrent (requiring treatment after curative-intent surgery or radiotherapy) adenocarcinoma of the prostate for which androgen deprivation or antiandrogen therapy (GnRH agonist/antagonist, bicalutamide/flutamide, surgical castration or enzalutamide/abiraterone monotherapy) is initiated as definitive treatment no longer than 3 months before recruitment
Willingness to participate and signing of informed consent
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Teemu Murtola, MD, PhD | Contact | +358-3 311 65015 | teemu.murtola@uta.fi | |
| Aino Siltari, PhD | Contact | aino.siltari@helsinki.fi |
| Name | Affiliation | Role |
|---|---|---|
| Teemu Murtola, MD, PhD | Tampere University Hospital | Principal Investigator |
| Otto Ettala, MD, PhD | Turku University Hospital | Study Director |
| Heikki Seikkula |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Herlev and Gentofte Hospital | Not yet recruiting | Herlev | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35487730 | Derived | Siltari A, Riikonen J, Koskimaki J, Pakarainen T, Ettala O, Bostrom P, Seikkula H, Kotsar A, Tammela T, Helminen M, Raittinen PV, Lehtimaki T, Fode M, Ostergren P, Borre M, Rannikko A, Marttila T, Salonen A, Ronkainen H, Loffeler S, Murtola TJ. Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open. 2022 Apr 29;12(4):e050264. doi: 10.1136/bmjopen-2021-050264. |
Not provided
Not provided
Sharing of individual-level data is not allowed by ethics board
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| OTHER |
| Fimlab laboratories | UNKNOWN |
| Helsinki University Central Hospital | OTHER |
| Kuopio University Hospital | OTHER |
| Oulu University Hospital | OTHER |
| Seinajoki Central Hospital | OTHER |
| The Hospital of Vestfold | OTHER |
| Telemark Hospital Trust | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
| Placebo oral capsule | Drug | Similar capsules as in the atorvastatin arm, but without the active ingredient |
|
| Prostate cancer mortality | Followed through Finnish national registries after reaching the primary end-point | From date of randomization until the date of prostate cancer death, assessed up to 60 months |
| Overall survival | Followed through Finnish national registries after reaching the primary end-point | From date of randomization until the date of death due to any cause, assessed up to 60 months |
| Circulating cell-free DNA | Occurrence of adverse tumor traits predicting development of castration resistance in circulating cell free DNA | At enrollment and at occurrence of castration resistance, assessed up to 60 months |
| Fasting blood glucose | To see how ADT affects glucose tolerance and whether atorvastatin intervention has any effect on it | From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 6 month intervals up to 60 months |
| Occurrence of cardiovascular events during ADT | Any cardiovascular events as described by the participant or evident from the patient files during the course of follow-up. Followed via national registries after meeting the primary end-point. | From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 6 month intervals up to 60 months |
| General quality of life (QOL) | Score from validated QOL questionnaire EORTC QLQ-C30 (range 0-100, with 100 denoting highest quality of life) | From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 12 month intervals up to 60 months |
| Prostate cancer-specific quality of life (QOL) | Score from validated QOL questionnaire EORTC QLQ-PR25 (range 0-100, with 100 denoting highest quality of life) | From date of randomization until the date of first occurrence of castration resistance or death, whichever came first, assessed at 12 month intervals up to 60 months |
| Central Finland Hospital District |
| Study Director |
| Tartu University Hospital | Recruiting | Tartu | Estonia |
|
| Helsinki University Hospital, Department of Urology | Recruiting | Helsinki | Finland |
|
| Central Finland central hospital | Recruiting | Jyväskylä | Finland |
|
| Kuopio University Hospital, Department of Urology | Not yet recruiting | Kuopio | Finland |
|
| Seinäjoki Central Hospital, Department of Surgery | Recruiting | Seinäjoki | Finland |
|
| Tampere University Hospital | Recruiting | Tampere | Finland |
|
| Turku University Hospital | Recruiting | Turku | Finland |
|
| The Hospital of Telemark | Recruiting | Skien | Norway |
|
| The Hospital of Vestfold | Recruiting | Tønsberg | Norway |
|
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D006538 |
| Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |